In patients with moderate-to-severe and severe psoriasis and high efficacy of therapy (PASI≥75) with signaling pathway inhibitors (apremilast, tofacitinib), cytokine spectra in the skin and blood plasma were studied using xMAP technology at baseline and on weeks 14 and 26 of treatment. Comparison of cytokine levels in psoriatic lesional skin and plasma samples of patients treated with apremilast or tofacitinib revealed statistical difference only for IFNγ level (р<0.05) at week 26.

中文翻译：

---

Janus 激酶抑制剂和磷酸二酯酶 4 抑制剂对银屑病患者皮肤和血浆细胞因子水平的影响

在使用信号通路抑制剂（阿普斯特、托法替尼）治疗的中度至重度和重度银屑病患者（PASI≥75）中，在基线和第 14 周使用 xMAP 技术研究皮肤和血浆中的细胞因子谱和 26 的治疗。比较接受阿普司特或托法替尼治疗的患者银屑病皮损和血浆样本中的细胞因子水平显示，仅在第 26 周时 IFNγ 水平有统计学差异（р <0.05）。